Piper Sandler raised the firm’s price target on Veeva (VEEV) to $290 from $280 and keeps an Overweight rating on the shares following Q3 results. The firm cited “solid execution” and increasing adoption intent across the “Top 20” biopharma firms for the price target raise.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV: